Literature DB >> 9308766

A type 2b von Willebrand disease mutation (Ile546-->Val) associated with an unusual phenotype.

A B Federici1, P M Mannucci, F Stabile, M T Canciani, N Di Rocco, S Miyata, J Ware, Z M Ruggeri.   

Abstract

Type 2B von Willebrand disease (vWD) is typically characterized by enhanced ristocetin-induced platelet aggregation (RIPA) caused by increased von Willebrand factor (vWF) affinity for platelets. Furthermore, absence of larger vWF multimers in plasma is characteristic of the originally described type IIB patients, now considered a subgroup of type 2B. We describe here three affected members of a family presenting with prolonged bleeding time, thrombocytopenia, markedly enhanced RIPA and spontaneous platelet aggregation, but normal plasma vWF antigen and ristocetin cofactor activity. Larger plasma vWF multimers, albeit decreased, were present in relatively greater proportion than in other type IIB patients. Genetic studies performed in two of these patients resulted in the identification of a previously unreported A-->G transition at nucleotide 4175 in the sequence of the pre-pro-vWF cDNA, corresponding to the substitution Ile546-->Val in the mature vWF subunit. This mutation appears to be responsible for an unusual type 2B phenotype, with greater enhancement of the vWF-platelet interaction than in typical cases but partial preservation of the larger vWF multimers in plasma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9308766

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(alpha)-vWF tether bond.

Authors:  Teresa A Doggett; Gaurav Girdhar; Avril Lawshé; David W Schmidtke; Ian J Laurenzi; Scott L Diamond; Thomas G Diacovo
Journal:  Biophys J       Date:  2002-07       Impact factor: 4.033

Review 2.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Exploiting the kinetic interplay between GPIbα-VWF binding interfaces to regulate hemostasis and thrombosis.

Authors:  Jianchung Chen; Hairu Zhou; Alexander Diacovo; X Long Zheng; Jonas Emsley; Thomas G Diacovo
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

4.  Changes in thermodynamic stability of von Willebrand factor differentially affect the force-dependent binding to platelet GPIbalpha.

Authors:  Matthew Auton; Erik Sedlák; Jozef Marek; Tao Wu; Cheng Zhu; Miguel A Cruz
Journal:  Biophys J       Date:  2009-07-22       Impact factor: 4.033

5.  Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF.

Authors:  Tadayuki Yago; Jizhong Lou; Tao Wu; Jun Yang; Jonathan J Miner; Leslie Coburn; José A López; Miguel A Cruz; Jing-Fei Dong; Larry V McIntire; Rodger P McEver; Cheng Zhu
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

6.  The venomous cocktail of the vampire snail Colubraria reticulata (Mollusca, Gastropoda).

Authors:  Maria Vittoria Modica; Fabrizio Lombardo; Paolo Franchini; Marco Oliverio
Journal:  BMC Genomics       Date:  2015-06-09       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.